Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:43 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
PKB171 Against Placebo in Couples With Asthenozoospermia Who Wish to Conceive
NCT06986031 · Prokrea BCN, S.L. · PHASE2 · terminated · last registry update 2025-05-22 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The trial was teriminated early due to low subject recruitment and high screening failure rates, despite several protocol modifications.” | – | Registry record, Prokrea BCN, S.L. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGS2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-18Results posted on the registry: Columbia University, I 124-Evuzamitide (NCT05635045)
- 2025-03-11Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) (NCT06871046)
- 2025-03-10Phase 3 first posted: Teikoku Seiyaku Co., Ltd., Esflurbiprofen Topical System (EFTS) + Placebo Patch (NCT06866613)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision